EGFR and inflammatory breast carcinoma: Previous studies have shown that the EGFR inhibitor erlotinib (TarcevaTM) significantly inhibited cell motility, invasiveness, tumor growth, and spontaneous lung metastasis in EGFR-expressing IBC models[31].